

Keyword Index for Volume 97

- 1p 1416
- 3-phosphoinositide-dependent protein kinase-1 1465
- 3D tumour model 194
- 5-fluorouracil 334, 910, 919, 1028, 1532
- adaptive conjoint analysis 717
- adenomatous polyposis coli 384
- adenosarcoma 1194
- adenovirus 992
- adjuvant chemotherapy 654, 1021
- adjuvant; neutropaenia 1642
- adolescent 29
- adrenal tumour 420
- adult T-cell leukaemia 1099
- advanced cancer 177, 1475
- advanced ovarian cancer 1200
- aerobic glycolysis 646
- aetiology 1287, 1291
- Affymetrix 1165
- ageing 1189
- AKT 218, 785, 809
- albumin 1266
- alcohol 118, 429, 700, 1287
- alkaline sphingomyelinase 1441
- ALL 992
- allelic imbalance 1157
- AML 877
- anastrozole 152
- androgen-independent 1206
- androgens 688
- androstene neuro-steroids 619
- aneuploidy 1218
- angiogenesis 391, 513, 1277, 1432, 1523, 1673
- angiopoietin family 877
- anilinoquinazolines 183
- anti-adhesion 730
- anti-EGFR treatment options 92
- anti-folates 1071
- antiangiogenic 65
- anticancer agent 1344
- antigen shedding 1146
- antihypertensive treatment 112
- antimetabolites 628
- anxiety 1625
- APC antibody specificity 384
- apoptosis 253, 277, 637, 769, 902, 1077, 1225, 1234, 1432, 1532, 1696
- aromatase 755
- aromatase inhibitor 152
- array-CGH 260
- asbestos 1300
- aspirin 1295
- attributable proportion 129
- audiovisual patient information 705
- Aurora-A 1664
- autologous transplantation 539
- awareness 691
- AZD2171 65
- B-CLL 769
- basement membrane 1505
- BCG-refractory 1499
- Bfl-1 769
- biliary tract cancer 1577
- biochemical recurrence 678
- biomarker 1, 1457
- biopsy 952
- bladder cancer 1499
- blood outgrowth endothelial cell 513
- blood pressure 112
- blood testing 1399
- blood-brain barrier 322
- body mass 1486
- body mass index 995, 1005
- bone metastasis 964
- bone tumours 1588
- bone turnover 964
- bortezomib 1099
- brain tumour 1583
- BRCA2 gene 826
- breast and bladder cancer 502
- breast cancer 58, 105, 152, 327, 434, 440, 479, 654, 686, 688, 725, 761, 809, 832, 957, 964, 978, 1046, 1090, 1157, 1175, 1211, 1251, 1277, 1287, 1361, 1372, 1505, 1523, 1570, 1625, 1632, 1642, 1673
- breast cancer susceptibility 1696
- breast conservation 725, 883, 1046
- breast surgery 1211
- [¹¹C]carvedilol 322
- c-Kit 857
- c-MET 368
- C-reactive protein 1266
- C4.4A 1146
- C6 cells 755
- Ca²⁺-binding protein 792
- cancer clinical trials 705
- cancer mortality 1300
- cancer services 1588
- cancer survivors 612
- cancer survivorship 1625
- cancer testis antigen 543
- cancer vaccine 1381
- capecitabine 712, 862, 1333, 1475
- carbonic anhydrases 1465
- carboplatin 162
- carcinogenesis 646
- carcinoma of an unknown primitive 857
- cardiotoxicity 1084
- case-control study 429, 434, 995
- caspases 1234
- CCR7 670
- CD9 941
- CDK4 1242
- CEA 745
- celecoxib 1206
- cell cycle 277, 1513
- cell cycle checkpoints 1664
- cell death 1381
- cell migration 1361, 1432
- cell-free DNA 1399
- cell-of-origin subtypes 1165
- central nervous system tumours 1588
- cervical cancer 129, 133, 218, 1322, 1457
- cervical carcinoma 1058
- cervix carcinoma 1135
- CESH 1707
- cetuximab 494, 1139
- CGH 238
- chemokine receptor 670
- chemoprevention 327
- chemoradiotherapy 712, 883
- chemoresistance 769
- chemotherapy 29, 862, 1028, 1040, 1157, 1234, 1642
- Chernobyl 818
- childhood acute lymphoblastic leukaemia 140
- childhood cancer 412, 695, 986, 1583
- childhood leukaemia 986, 1009, 1315
- Chile 85
- China 123, 1577
- Chlamydia* 949
- cholecystitis 1577
- chromosomal instability 1218
- chromosome 1696, 1707
- chronic lymphocytic leukaemia 253
- cigarette smoking 700
- circumferential resection margin 1333
- cisplatin 162, 194, 712, 851, 1234, 1329
- clear cell adenocarcinoma 1053
- clear cell renal cell carcinoma 420
- clinical decision support systems 486
- clinical phase II study 1084
- clonality 1260
- coffee 426, 1291
- cognitive behaviour therapy 612
- cohort 686, 1295, 1570
- cohort studies 115, 118, 123, 129, 426, 1005, 1291, 1300
- collagen I 358
- colon cancer 1021, 1655
- colorectal adenoma 1425, 1449
- colorectal cancer 297, 446, 745, 971, 978, 1028, 1035, 1139, 1146, 1266, 1305, 1425, 1486, 1606
- colorectal cancer cells 384
- colorectal neoplasms 118, 1393, 1601
- colorectal tumours 92
- combination index 628
- combination treatments 888
- communication skills 472
- comparative genomic hybridisation 1707
- computer simulation 1322
- conformal radiation 464
- convection 194
- copper transporter ATP7A 334
- cost-effectiveness analysis 152, 1322
- cost-utility analysis 152
- Costa Rica 837
- costs 479
- COX-2 inhibitor 1206
- COX2 557
- coxibs 1465
- CRH 637
- CS-682 628
- CXCL12 761
- CXCR4 761
- cyclooxygenase-2 1388, 1523
- cyclooxygenase-2 independence 1465
- cyclophosphamide 1200
- CYP3A4 metabolism 440
- cytokines 105, 210
- cytotoxic T lymphocyte 1648, 1655
- DDS 170
- deep-vein thrombosis 1053
- degradome 201
- degranulating CD8⁺ cells 1381
- dendritic cells 1251
- depression 1625
- deprivation 999
- detection methods 1632
- diabetes 995
- Dickkopf-1 964
- dietary iron 118
- diffusion 194
- disease progression 1469
- disease-free survival 50
- Dkk-1 1552
- DNA crosslinking 253, 927
- DNA damage 1189
- DNA hypomethylation 412
- DNA methylation 895, 1457
- DNA repair 334, 927
- docetaxel 290, 593, 851, 1206, 1338, 1475, 1613
- doctor discipline 6

- doctor specialty 6
 dose intensity 1642
 dose-limiting toxicity 177
 downstaging 851
 doxorubicin 43, 1084
 doxorubicin resistance 1077
 drug delivery 194, 735, 910
 drug development 577
 drug resistance 562, 927, 1218
 ductal carcinoma *in situ* (DCIS) 725
 dynamic models 1322
 dysplasia 1545
- E-cadherin 358
 E2F 1242
 early-onset disease 826
 EBV 1567
 EGFR 453, 494, 659, 778, 857, 1139, 1560
 EGFR downstream signalling pathway 92
 EGFR mutations 741, 1560
 elderly 162, 1606
 ELISA 398
 embryonic tumours 412
 endometrial cancer 995, 1538, 1194
 endoplasmic reticulum (ER) stress 1465
 endoscopy 1493
 endostatin 513
 endovascular instillation 1499
 England 989
 ENPP7 1441
 EpCAM (CD326) 315
 epidemiology 112, 1287, 1583
 epidermoid cancer 1234
 epigenetic process 1116
 epigenetics 1, 267, 562, 986, 1416
 epirubicin 1200
 ErbB2 659, 1354
 ErbB2 mutation 741
 ErbB3 453
 ESCC 1409
 esophageal cancer 218
 estramustine 1206, 1613
 etoposide 162
 expectations 14
 extracellular matrix 201
- α -fetoprotein 327
 FACS 73
 faecal occult blood 1601
 Fas ligand 73, 637
 fatigue 612
 FDG-PET 902, 1493
 fetal origins of disease 686
 fibroblasts 210, 398
 first-line treatment 297
 fluorescent *in situ* hybridisation 1139
 foetal haemoglobin 412
 folate 1449
 folate metabolism 247
 FOLFIRI 1035
 follow-up 1632
- G₁ phase 1242
 galectin-3 1146
 gallstones 1577
 GAMEC 308
 gastric adenocarcinoma 458
 gastric cancer 37, 123, 543, 550, 589, 700, 712, 837, 851, 902, 1493, 1567
 gastric cancer screening 837
 gastric carcinoma 334
 GDEPT 745
 gefitinib 65, 183, 778, 1560
 gemcitabine 43, 145, 283, 464, 1329, 1499
 gene expression 145, 895
 gene expression profiling 1432
 gene fusion 1690
 gene therapy 513
 genetic alterations 260
 genetic susceptibility 1701
 genetics 1305
 genomics 1116
 germ cell 308
 glioblastoma 302, 619
 glioma cells 755
 glucose transport 902
 glucose-regulated protein 94 kDa 792
 GLUT-1 646
 glycosaminoglycan 761
 glycosylation 1146
 grapefruit intake 440
GSTP1 1399
 Guthrie cards 992
- haematological malignancies 1588
 haeme oxygenase-1 1683
 haplotype 832
 HCC 1399
 HCV 1399
 HDAC 1344
 HDAC inhibitor 177, 1344
 head and neck cancer 65, 670
 hemangiosarcoma 115
 heme iron 118
 heme oxygenase-1 1099
 hepatic resection 1606
 hepatitis C virus 426
 hepatocellular carcinoma (HCC) 50, 426, 582, 862, 1260, 1532
 HepG2 1441
 HER dimerisation inhibitors 1338
 HER-2 105, 453, 494
 Her-2/neu overexpression 857
 HER-3 453
 hereditary 486
 hetastatic breast cancer 1040
 hexokinase 902
 high-dose chemotherapy 308, 391, 1200
 high-risk breast cancer 391
 histone modifications 1
 histopathology 1393
 HLA-A3 supertype 1648
 HMEC 1361
- Hodgkin lymphoma 29
 Hodgkin's 1310
 homocysteine 1071
 hormonal 1194
 hormone replacement therapy 118, 1486
 hormone-refractory 378, 1480
 hormones 688
 HPV 218
 HPV infection 133
 HPV vaccination 1322
 HRQOL scores 302
 Hsp90 741
 human gastric cancer 895
 human papillomavirus 85, 691
 hypercalcaemia 183
 hypericin 502
 hypermethylation 267
 hypertension 995
 hypomethylation 267
 hypoxia 646
- IBC signature 1165
 Id proteins 1409
 IL-6 378
 IL-6R 378
 imatinib 735
 immune function 1251
 immune privilege 637
 immunohistochemistry 398, 405, 523, 531, 1135, 1404
 immunostaining 952
 immunotherapy 210, 315, 598, 1354
 immunotherapy CD40 1251
 impact evaluation 837
 improvement 1469
 incidence 1009, 1567
 individual dosing 290
 indomethacin 1077
 infection 1310
 inflammatory breast cancer 659, 883
 inhibitor of apoptosis 1271
 insulin 98
 insulin-like growth factor 98
 insulin-like growth factor binding protein 98
 integration 85
 integrins 1090
 interferon resistance 231
 interferon- γ 420
 interleukin-6 1513
 international differences 1277
 interphase FISH 678
 interstitial fluid pressure 735
 intervention 612
 invasion 73, 358, 368, 1505
 invasiveness 50
 ionising radiation 1664
 irinotecan 297, 593, 1035
 irradiation 322
 isolated tumour cells 589
- JAK 378
 JNJ-16241199 1344
- K-Ras 1139
K-ras/BRAF mutations 1425
 Ki-67 1124
 KIF2C 543
 kinase inhibition 741
 knowledge 691, 705
- Lactobacillus rhamnosus* GG 1028
 late complication 1058
 Lck 1648
 left-handedness 686
 letrozole 802
 leucovorin 297
 leukocytes 978
 lifestyle factors 133
 ligand interactions 1361
 liver cancer 1005
 liver diseases 1441
 liver metastases 1035
 liver tumour 1441
 Livin/ML-IAP/KIAP 1271
 local recurrence 1046
 locally advanced rectal cancer 1333
 locoregional relapse 1632
 long-term effect 612
 loss of heterozygosity 1157
 lung cancer 85, 183, 247, 735, 1295, 1300
 lymphadenectomy 1194
 lymphoma 539, 619, 1310
- malignant glioma 619
 malignant melanoma 231
 mammary carcinoma 1354
 marker 1545
 Masaoka's staging system 22
 mass screening 1601
 mast cells 952
 maternal 688
 mathematical models 646, 1322
 matrikine 1505
 matrix metalloprotease 1106
 matrix metalloproteinase 398, 971, 1505
 maximum tolerated dose 177
 MCAK 543
 MCM-2 1124
 MCM-5 1124
 MDA-MB-231 1361
 medical education 472
 medulloblastoma 267
 melanoma 223, 1225, 1329
 melatonin 755
 mesenchymal stem cell 1552
 mesothelioma 1300
 meta-analysis 1005, 1291
 metastasis 223, 670, 761, 868, 957, 1409, 1523, 1606
 metastatic breast cancer 1040
 metastatic gastric cancer 593
 methotrexate 308
 methylation 1425
 microarray 818
 microdose 577
 micrometastasis 550

- micronuclei 1218
microtubule 1218, 1673
microtubule inhibitors 888
microvessel density 391, 405, 1277
midkine 405
migration 543, 1090
minimum dataset 1393
mitochondria 345
mitogen-activated protein kinase 659
mitomycin 1475
mitotic catastrophe 941
mitoxantrone 1613
MMP 957
modulation 919
molar pregnancy 986
monoHER 1084
monohydroxyethylrutoside 1084
monounsaturated fat 1570
morphine 1523
mortalin 941
mortality 1009
mortality trends 1588
motility 358
MRP1 1077
MS-MLPA 1457
Ms-SNuPE 1457
MSC 1552
MSP 1457
MT1-MMP 358
MUC-1 730
MUC1 O-glycosylation 910
MUC4 345
mucin 345
multicell layer 194
multicentric occurrence 1260
multidrug resistance 502, 934
multifocal low-grade urothelial cancer 260
mutation 778, 1416
Mycoplasma 949
- N*-acetylglucosaminyltransferase V 1538
natural killer cells 539
neoadjuvant 1035
neoadjuvant chemoradiotherapy 1333
neoadjuvant chemotherapy 589
neoplastic syndromes 486
nested case-control study 426, 446
neuroblastoma 210, 238, 1416
neuron-glia-related cell-adhesion molecule 531
neuroligins 1090
neutropenia 37
NF- κ B 523, 659, 745, 1165
NHE 646
NK cytotoxicity 105
NK105 170
non-small-cell lung cancer 283, 741, 1560
NSAIDs 557
nuclear localisation 1683
nucleoside analogue 628
nucleoside diphosphate kinase 1372
obesity 1005
occupational exposure 1300
octreotide 582
oesophageal cancer 123, 494, 868
oesophagus 1404
oestrogen receptor 58, 659
offspring gender 688
oncogenes 1189
opioids 1523
OPN 1545
oral squamous cell carcinoma 792
osteonectin 1106
osteosarcoma 1552
outcome 1632
ovarian adenocarcinomas 1124
ovarian cancer 358, 637, 927, 1053, 1291, 1618
ovarian low malignant potential tumours 1124
overall response rate 1618
overrepresentation analysis 1432
oxaliplatin 593, 862
oxaliplatin resistance 334
oxidative stress 1683
- P-glycoprotein 322, 934
p16INK4A 1242
P2Y receptors 1372
p53 58, 1225, 1532, 1664
paclitaxel 43, 170, 888, 1218
palliative care 283, 472
pancreatic cancer 464
pancreatic adenocarcinoma 598, 1106
pancreatic cancer 98, 345, 405, 523, 910, 1432
pancreatic neoplasms 1116
pangenomic analysis 238
panitumumab 1469
papillary thyroid carcinoma 531
papillomavirus 129
papillomavirus, human 989
parental occupation 1315
passive smoking 434
pathology 654
pathway analysis 792
patient recruitment 705
patient-centred assessment 1063
patient-reported outcomes 1469
PBD dimer 253
PDK-1 785
pegylated interferon 1532
pemetrexed 1071
peptides 1648, 1655
performance status 458
pericellular proteolysis 201
peritoneal dissemination 550
pertuzumab 1338
PHA680632 1664
pharmacodynamic markers 1071
pharmacodynamics 290, 577
pharmacogenomics 145
pharmacokinetics 43, 290, 577
phase 0 trial 577
phase I 844, 1338
phase I study 170
phase I/II study 712
phase II study 862, 1480
phosphorylated Akt 92
phosphorylated MAPK 92
photochemical internalisation 502
photodynamic therapy 502, 1381, 1513
physical activity 995
PI3K/Akt 453
PIK3CD 1416
pineal 755
plasma 25-hydroxyvitamin D 446
plasma D-dimer 1053
plasma deoxynucleosides 1071
platelets 978
platinum chemotherapy 927
platinum-resistant 1618
platinum-sensitive 1618
PLD1 809
polymer micelles 170
polymorphisms 145, 557, 1175, 1449
polyphenolic compounds 1372
polyunsaturated fat 1570
poor prognosis 792
poor-risk 162
population analysis 290
population dynamics 140
population study 29, 112, 730
population-based cohort study 986
positive lymph nodes 605
post-cancer fatigue 612
postmenopausal 1486
postnatal vasculogenesis 513
poverty 140
PPAR 1388
predicting factor 405
predisposition 1305
preeclampsia 688
premenopausal 802
prenatal infection 992
preoperative 802
primary colon cancer cells 73
primary health care 486
primary therapy 802
probiotic 1028
profilin 1361
prognosis 1, 37, 238, 247, 523, 550, 957, 1211, 1409, 1690
prognostic factors 302, 391, 605, 952, 1538
prognostic marker 678, 730, 877
programmed cell death 619
progression-free survival (PFS) 1538, 1618
proline-rich tyrosine kinase2 (Pyk2) 50
promoter 277
promoter hypermethylation 1260
prostate cancer 378, 557, 730, 826, 941, 952, 978, 1206, 1480, 1613, 1673, 1683
prostatic neoplasms 1690
proteasome inhibitor 1099
protein-truncating *BRCA2* mutations 826
proteomics 1116
PSA 678
psychosocial 1063
PTEN 1139
PTEN haploinsufficiency 678
PTHrP 183
pulmonary MALT lymphoma 949
pulmonary thromboembolism 1053
- quality of life 283, 1469, 1625
quantitative RT-PCR 531
- R306465 1344
race 14, 140
radiation 1058, 1505
radiation effects 115
radiation susceptibility 818
radiosensitivity 1696
radiotherapy (RT) 65, 115, 725
randomised trial 486, 1200
rapamycin 809
Ras signalling pathway 1425
RASSF2 1425
real-time methylation specific PCR 1260
real-time PCR 1399
recurrence 50, 479
red meat 118
RelA 523
relative survival 999
renal cell cancer 112, 429, 1271
resistance 919
rhabdomyosarcoma 785
risk 971, 1486
- S-1 37, 458, 851
S100 267
S6 kinase 218
sarcoma 115, 1194
saturated fat 1570
SCC 1545
Scotland 999
screen-detected 725
screening 129, 971, 1493
second cancer 1058
second soft tissue sarcoma 695
SEER-Medicare 1606
self-report 14
sentience 941, 1225
sensitivity 1493
sequential chemotherapy 1613
seroepidemiologic studies 989
serum 778, 978
SFRPs 895
shared decision-making 6
signal transduction 368

- single nucleotide polymorphism 832
 siRNA 384
 SJG-136 253
 skin reactions 14
 Smad-pathway 1388
 small molecular inhibitor 785
 small molecule 1344
 small-cell lung cancer 162, 368, 1077
 smoking 434, 1287
 SNP 247
 social contact 1315
 social difficulties 1063
 socioeconomic inequalities 999
 socioeconomic status 140
 SOCS proteins 231
 solid tumours 539, 844
 soluble interleukin-6 receptor 1513
 somatostatin analogues 582
 sorafenib 1480
 spermatocytic seminoma 1707
 squamous cell carcinoma 1404
 St Gallen expert consensus meeting 654
 stage II 1021
 staging 868, 1393
 STAT 378
 STAT phosphorylation 231
 stealth liposome 919
 stellate cells 1106
 stem cells 1189
 stereology 1135
 stromal 1194
 subsite 700
 superoxide dismutase 2 1116
 surgery 1690
 survival 283, 523, 670, 1124, 1266, 1567
 symptom 1469
 synergy 253, 628
 synthetic vectors 210
 T-cell signalling proteins 105
 tailor-made therapy 145
 tamoxifen 152, 327, 582
 tea 1291
 teenage and young adult cancer 1588
 telomere 832, 1696
 temozolomide 1225
TERF2 832
TERT 832
 testicular germ cell tumour 1701, 1707
 testicular microlithiasis 1701
 TGF- α 1388
 TGF- β signal 1388
 the Sloane Project 725
 three weekly schedule 1040
 thymic epithelial tumour (TET) 22
 thymidine phosphorylase 745
 thymidylate synthase 334, 1242, 1449
 thymidylate synthase inhibition 1071
 thyroid cancers 818
 time-dependent variable 37
 TIMP 957
 tissue microarray 785
 titanocene 1234
 TMX2-28 cells 809
 TNM stage 1266
 toll-like receptor 598
 tonsil 670
 topoisomerase II 58
 total dietary fat 1570
 toxicity 577, 712
 TP53 1157
 trabectedin 1618
 TRAIL 73
 transcription 277
 transformation 1457
 transforming growth factor- β 398, 1106
 transforming growth factor- β receptor 1 1175
 trastuzumab 494
 treatment 14
 treatment decisions 6
 treatment outcomes 717
 treatment preference 717
 treatment tradeoff method 717
 trends 1009
 treosulfan 1329
 trichostatin A 562
 trifunctional antibodies 315
 tumour 277, 513
 tumour angiogenesis 1372
 tumour immunity 1655
 tumour infiltrating lymphocytes 1135
 tumour marker 412
 tumour microenvironment 398, 1106
 tumour therapy 1271
 tumoural invasion 957
 twenty year follow-up 730
 tyrosine kinase inhibitor 65, 453
 tyrosine kinase receptor 857
 UFT 297
 undergraduate 472
 urbanisation 140
 uterine cancer 605
 valproic acid 177
 vascular disrupting 888
 vascular endothelial growth factor 391
 VEGF 851
 VEGF family 877
 VEGF-C 1090
 VEGF₁₆₅b 223
 VEGF_{xxx}b 223
 vinorelbine 283
 viral load 85
 vitamin D 123
 weekly docetaxel 1040
 weekly epirubicin 1040
 western blot 531
 white cells 1266
 WHO histologic classification 22
 Wnt signalling 964
 wound healing 1211
 X-ray 1583
 xanafide 58
 XELOX 862
 xenografts 73, 919
 XR5944.14 844
 young age 1046
 ZD1839 183
 ZD6126 888
 ZD6474 934